Bipartisan Bill Seeks FTC Probe of Foreign Drug Supply
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bipartisan lawmakers reintroduced a bill Wednesday requiring the Federal Trade Commission and Department of Treasury to probe U.S. reliance on foreign countries for prescription drug production.
- The legislation specifically directs an examination of whether risks are increased by relocating domestic manufacturing facilities to foreign countries.
- The bill reflects mounting concern that the U.S. pharmaceutical supply chain is vulnerable to disruptions that could become a national security issue.
- Lawmakers cited China's dominant role in producing many essential materials needed for medicines taken by Americans as a key driver of the legislation.
- A U.S. Department of Defense watchdog concluded five years ago that overreliance on foreign medicine suppliers could harm national security.
- The same watchdog found that the Pentagon failed to assess the risks of drug shortages or develop strategies to mitigate supply disruptions.
Why it matters: If enacted, the bill would create formal federal accounting of which critical medicines and ingredients come from abroad — giving Congress and regulators a documented basis to act on the supply-chain vulnerability that a Pentagon watchdog flagged five years ago without remediation. Drug manufacturers and supply-chain investors would face new transparency about where their inputs originate, while patients relying on China-sourced materials for essential medicines stand to be most exposed if disruptions materialize.
